Kornimate/medical-research-clean huggingface dataset:
surgical management of cerebral arteriovenous malformations within hybrid operation room

Conditions: Intracranial Arteriovenous Malformations

Summary: to evaluate the clinical benefits and risks of hybrid operating techniques in management of cerebral arteriovenous malformations.

purpose: have an evaluation of clinical benefits and risks of hybrid operating techniques in management of cerebral arteriovenous malformations(avms). meanwhile, as a new cooperative interventional modality, optimized workflows, technical key knots and operation routines will be explored in the study. objects: patients with cerebral arteriovenous malformations, coincident with inclusion and exclusion criterion and admitted in participating organizations. methods: patients will be distributed into 2 groups, including traditional therapy group(control group) and hybrid operating group(trial group), and conduct with traditional neurosurgical management or one-stage hybrid operating management correspondingly. residual rate of avm is considered to be the primary observing indicator, and morbidity rate of post-operative complications, post-operative mortality rate, and morbidity rate of neural functional deterioration are secondary indicators.the information of operations will be recorded in detail as evidence of optimization of workflow and technical key knots.

Eligibility criteria:
inclusion criteria: * newly ruptured avm with stable hematoma, selective operation is practical; * with rupture history; * recurrent epilepsy, failed in aed management; * giant avm with deterioration of neurological functions; * 1-4 grade avm (spetzler-martin grading system) with no symptom and not located in eloquent area. exclusion criteria: * \>70 in age, with low rupture risk; * newly ruptured avm with unstable hematoma, engaged in emergency operation; * ≥5 grade in spetzler-martin grading system; * avm located in hypothalamus, brainstem, cerebellopontine angle; * cannot tolerant the operation; * patient or relative refuses to participate the trail.

Keywords: intracranial arteriovenous malformations
ultrasound guided percutaneous microwave ablation for breast lesions

Conditions: Neoplasm of Breast

Summary: the investigators will perform this study to prospectively analyse the clinical outcome after percutaneous microwave ablation(mwa) of benign and malignant breast lesion under ultrasound (us) guidance.

a total of more than 500 patients diagnosed with benign breast lesions and 50 patients with malignant breast lesions in seven centers of china will be recruited in this study and underwent us-guided percutaneous mwa treatment. information for each patient includes demographics; longest diameters of tumors; tumor numbers; tumor pathological type; location of tumor according to whether adjacent to skin, pectoralis, areola and papilla. ablation variables including session, puncture, time, and power; complete ablation, complications; reduction in volume, palpability, pain and cosmetic satisfying outcomes,recurrence,survival will be measured and analyzed.

Eligibility criteria:
inclusion criteria: * breast lesion proved by using core-needle biopsy; * for benign lesions,lesion 1.0 cm or larger in greatest diameter and continually increasing during a half year follow-up; for malignant ones, lesion size 2cm or smaller; * distance of at least 1.0cm to papilla with the patients supine; * the symptoms of local pain, discomfortable or compression considered probably relating to the lesion of breast; * the patient with evidently psychological pressure due to the occurrence of the lesion; * patients unwilling or refused to receive other treatment and presence of an appropriate route for percutaneous puncture under us guidance. exclusion criteria: * patients who were pregnant or breast-feeding; * patients with evidence of coagulopathy or acute or severe pulmonary insufficiency or heart dysfunction; * patients during menstrual period; * patients who wanted to undergo other therapies including surgical excision and vacuum-assisted biopsy.

Keywords: microwave ablation breast multicenter
a study to evaluate the effect of vagus nerve stimulation in patients undergoing vt ablation

Conditions: Arrhythmia; Ventricular Tachycardia (VT)

Summary: vagus nerve stimulation (vns) has been shown to be beneficial in multiple studies including heart failure. the goal of this clinical investigation is to gain additional information about how vagus nerve stimulation relates to abnormal heart rhythms. the outcomes of this study will help researchers design new therapies for patients that have complex and life-threatening ventricular arrhythmias.

this study is a non-randomized, prospective study in 6 patients with scar mediated ventricular arrhythmias who are scheduled to undergo a catheter ablation procedure. the study will last up to 30 minutes in the cardiac electrophysiology lab. cervical vns is performed percutaneously through the internal jugular vein during the patient's routine ventricular tachycardia (vt) ablation procedure.

Eligibility criteria:
inclusion criteria: * presence of structural heart disease as defined as ef ≤ 50% or presence of ventricular scar as detected by imaging modalities or electroanatomic mapping, hypertrophic cardiomyopathy, cardiac sarcoidosis, or arrhythmogenic right ventricular cardiomyopathy. * age \> 18 years old * underlying sinus rhythm with heart rate \> 50 bpm. * provision of signed/dated informed consent and stated willingness to comply with all study procedures exclusion criteria: * active ongoing cardiac ischemia as assessed by: ecg, cardiac enzymes, symptoms, coronary angiography with evidence of significant epicardial coronary stenosis (\>70%), or stress testing. (note: positive troponin assay due to internal cardiac defibrillator (icd) shocks is not an exclusion criterion). * status post orthotopic heart transplantation * women who are pregnant (as evidenced by pregnancy test if pre-menopausal). * unable or unwilling to comply with protocol requirements. * known channelopathy such as long qt syndrome, brugada syndrome, and catecholaminergic polymorphic vt. * known peripheral neuropathy or history of autonomic dysfunction due to non-cardiac causes. * new york heart association class iv heart failure or use of current vasopressor medications * incessant vt * persistent atrial fibrillation * frequent premature atrial or ventricular contractions * inability to give informed consent.

Keywords: arrhythmia vagus nerve stimulation (vns) activation recovery interval (ari)
incidence & predictors of mechanical abnormalities of quicksite® and quickflex® left ventricular pacing leads

Conditions: Left Ventricular Pacing Leads

Summary: on april 2, 2012 the manufacturer of the quicksite® and quickflex® leads, st. jude medical, released a voluntary medical device advisory regarding these leads' potential for problems with the silicone insulation covering one end of the lead, where it meets another section of the lead which is coated with a different insulating material (polyurethane). there has been a voluntary suspension of sales of these leads. there are approximately 179,000 of the above leads implanted worldwide with an estimated 101,000 leads currently in service (59,000 in us). there have been 39 confirmed cases of the conductor portion of the lead becoming exposed from the silicone insulation (externalization), and the rate of occurrence of this type of problem is conservatively estimated at less than one percent. however, a review done by st. jude medical of returned quicksite® and quickflex® leads and available x-ray and fluoroscopic (x-ray movie) images of patients with these leads (from 1,219 patients) revealed a higher rate of 3-4%. it is presumed that there are patients whose leads have not yet been affected by this problem, but whose leads may show signs of structural changes on x-ray or fluoroscopy. this study seeks to determine what structural changes may be occurring in these leads, what signs might predict these changes, and what impact these changes may have on the lead and its performance.


Eligibility criteria:
inclusion criteria: * patient that received quicksite or quickflex lead at the university of kansas hospital exclusion criteria: * not willing to consent to data collection

Keywords: quicksite quickflex st. jude medical
the quantitative changes in palatal donor sites thickness after free gingival graft harvesting

Conditions: Healthy; Gingival Recession

Summary: our primary objective in this clinical intervention study, therefore, was to explored the effect of residual tissue thickness on the palatal mucosa healing from baseline to 1, 3 and 6 months after free gingival graft harvesting in order to determine as soon as possible to re-harvest gingival graft from same site.

forty individuals (19 males and 21 females; age range: 18-35 years) were enrolled in the study. based on the remaining tissue at donor site after free gingival graft harvesting, individuals were divided into two groups: 1.0-1.9 millimeter (mm) remaining tissue at donor site after harvesting (n = 20), 2-2.9 mm remaining tissue at donor site after harvesting. tissue filling in defect area from three points (mesial, central and distal) was measured at various time-points (baseline, post-operative 1, 3, 6 months).

Eligibility criteria:
inclusion criteria: * all individuals received oral hygiene instructions and full-mouth scaling was performed. -they were instructed to perform a non-traumatic brushing technique (roll) using an ultra-soft toothbrush * individuals were re-evaluated at 8 weeks after initial therapy, and only full mounth plaque score and full mounth bleeding score \<15% were enrolled to the surgical procedure * mucogingival defects which for soft tissue graft application were indicated * for less than 2 mm group, between 2.5 and 3.4 mm palatal thickness at each measurement points before graft harvesting * for 2 mm or more group, between 3.5 and 4.4 mm palatal thickness at each measurement points before graft harvesting. exclusion criteria: * periapical or palatal pathologies, * absence teeth from canine to first molar, * excessive forces including mechanical forces from orthodontics and occlusion, * systemic diseases that would contraindicate for periodontal surgery or interfere with tissue healing, chronic high-dose steroid therapy, radiation or immunosuppressive therapy, pregnancy, lactation, smoking, or allergy or sensitivity to any drug * study participants had no history of drug therapy known to interfere with healing and to cause gingival enlargement * individuals who had complication such as bleeding, necrosis and delay healing during or after surgery were excluded from the study.

Keywords: free gingival graft palatal donor site healing
cardiovascular outcomes study of naltrexone sr/bupropion sr in overweight and obese subjects with cardiovascular risk factors (the light study)

Conditions: Obesity; Overweight

Summary: the purpose of this study is to determine the effects of nb relative to placebo on major adverse cardiovascular events (mace) such as cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke in overweight and obese subjects who are at a higher risk of having these events because they have diabetes and/or other cardiovascular risk factors.


Eligibility criteria:
inclusion criteria: 1. ≥50 years of age (women) or ≥45 years of age (men) 2. body mass index (bmi) ≥27 kg/m2 and ≤50 kg/m2 3. waist circumference ≥88 cm (women) or ≥102 cm (men) 4. at increased risk of adverse cardiovascular outcomes: * cardiovascular disease (confirmed diagnosis or at high likelihood of cardiovascular disease) with at least one of the following: * history of documented myocardial infarction \>3 months prior to screening * history of coronary revascularization * history of carotid or peripheral revascularization * angina with ischemic changes (resting ecg), ecg changes on a graded exercise test (gxt), or positive cardiac imaging study * ankle brachial index \<0.9 (by simple palpation) within prior 2 years * ≥50% stenosis of a coronary, carotid, or lower extremity artery within prior 2 years and/or * type 2 diabetes mellitus with at least 2 of the following: * hypertension (controlled with or without pharmacotherapy at \<145/95 mm hg) * dyslipidemia requiring pharmacotherapy * documented low hdl cholesterol (\<50 mg/dl in women or \<40 mg/dl in men) within prior 12 months * current tobacco smoker exclusion criteria: 1. myocardial infarction within 3 months prior to screening 2. angina pectoris grade iii or iv as per the canadian cardiovascular society grading scheme 3. clinical history of cerebrovascular disease (stroke) 4. history of tachyarrhythmia other than sinus tachycardia 5. planned bariatric surgery, cardiac surgery, or coronary angioplasty 6. history of seizures (including febrile seizures), cranial trauma, or other conditions that predispose the subject to seizures 7. history of mania or current diagnosis of active psychosis, active bulimia or anorexia nervosa (binge eating disorder is not exclusionary) 8. any condition with life expectancy anticipated to be less than 4 years (e.g., congestive heart failure nyha class 3 or 4)

Keywords: body weight bupropion cardiovascular diseases diabetes mellitus diabetes mellitus, type 2 endocrine system diseases glucose metabolism disorders heart diseases metabolic diseases narcotic antagonists naltrexone nutrition disorders obesity overnutrition overweight
an observational study on real-world use and outcomes of patients treated with tolvaptan for hyponatraemia due to siadh

Conditions: Hyponatremia; Syndrome of Inappropriate ADH (SIADH) Secretion

Summary: this is a retrospective chart review non-interventional study designed to collect real world data on the use and outcomes of tolvaptan for the treatment of patients with hyponatraemia secondary to syndrome of inappropriate antidiuretic hormone (siadh) secretion.


Eligibility criteria:
inclusion criteria: * provision of patient informed consent unless a) not required by local regulations, b) it would take a non reasonable effort or c) if the source patient is deceased or untraceable. * female and/or male patients aged 18 years and over. * patients who received at least 2 doses of tolvaptan, for the treatment of one occurrence of hyponatraemia secondary to siadh. exclusion criteria: * a patient cannot take part in this study if participating in any other clinical study in which the medicinal product aims to treat the causes or symptoms of hyponatraemia at the time of the hyponatraemia episode being documented in the current study.

Keywords: hyponatremia due to siadh tolvaptan
the effectiveness of vestibulectomy

Conditions: Vulvodynia

Summary: women with vulvodynia will fill out a questionnaire and undergo a gynecological examination before and 6 months after vestibulectomy. the investigators hypothesize that pain will decrease.


Eligibility criteria:
inclusion criteria: * vulvodynia, scheduled for vestibulectomy

Keywords: vulvodynia vestibulectomy surgery vestibulitis
pediatric obesity research registry

Conditions: Obesity

Summary: the pediatric obesity research registry will function to collect and catalog historical and medical chart related clinical data of patients presenting with pediatric obesity and who agree to participate.

individuals between age 1 and 18 years who present to the endocrinology clinic for management of elevated bmi/obesity (body mass index≥95th percentile of age and gender), will be given the opportunity to read the consent form, have any questions/ concerns addressed prior to obtaining informed consent from the research team (consisting of the pi and the co-investigators) who are also part of the child's clinical care team. the child's clinician will introduce the study to the parents. the investigator will obtain written informed consent from the child's parents. the clinical care team/research registry investigators will address any questions and concerns prior to obtaining written informed consent and any future questions and concerns. in this manner, patients seen at the phoenix children's hospital (pch) division of endocrinology and diabetes with an obesity diagnosis will be asked to provide their written informed consent to allow their past, current and future identifiable medical record information related to their obese condition to be placed in the pediatric obesity research registry. for individuals who respond to potential advertisement or who contact the research team over the phone, a verbal explanation will be given over the phone and an offer to send a copy of the consent via mail/fax/email, and if interested scheduling a follow up appointment. at the clinic visit, the above noted procedure will be followed.

Eligibility criteria:
inclusion criteria: * individuals between age 1 and 18 years who present to the endocrinology clinic for management of elevated bmi/obesity * individuals between age 1 and 18 years who respond to advertisement or who contact the research team over the phone, for management of elevated bmi/obesity (body mass index ≥ 95th percentile of age and gender) exclusion criteria: * a body mass index less than 95th percentile of age and gender
sharable knowledge mining platform

Conditions: Liver Cancer

Summary: as a result of increasing adoption of health information systems in hospitals, more and more health records can be gathered and accumulated in the healthcare data repository. for this reason, the opportunity of analyzing and mining the healthcare data for quality improvement is increasing and becoming more and more important. the purpose of the project is to gather the clinical data relevant to liver cancer, and adopt the knowledge discovery and mining modules in information technology (it) for analyzing and discovering the knowledge from the gathered clinical data. we can analyze the gathered clinical data for comparing the outcomes of different treatment strategies, finding out new diagnosis and staging criteria and factors, and other hidden knowledge included in the clinical data. afterwards, the discovered results and the mining algorithms can be shared though the sharable knowledge mining platform provided by our project.


Eligibility criteria:
inclusion criteria: * clinical data of patients with liver cancer. (icd9 code is 155.0) * males and females

Keywords: liver cancer data mining knowledge discovering the clinical data of the patients with liver cancer.
vitamin d supplementation in older adults with urinary incontinence

Conditions: Urinary Incontinence; Vitamin D Deficiency

Summary: urinary incontinence (ui) is a common disorder among older women that greatly affects quality of life. emerging evidence from observational studies links vitamin d insufficiency with ui. prior to a larger intervention trial of vitamin d among older women with low serum vitamin d levels and urgency ui, we propose a pilot study in 100 older women comparing weekly, oral vitamin d3 50,000 iu to placebo. we hypothesize that adequate vitamin d supplementation will improve ui symptoms in older women with vitamin d deficiency. changes in ui-episodes will be assessed by a 7-day bladder diary and other validated symptom measures administered at baseline and after 12-weeks of intervention. serum calcium and 25(oh)d levels will be monitored. the expected outcomes will provide new knowledge regarding the impact of vitamin d supplementation on ui symptom improvement and inform a larger, randomized controlled clinical trial involving vitamin d supplementation.


Eligibility criteria:
inclusion criteria: (1) post-menopausal women (age ≥50 years of age); (2)urine leakage for 3 or more months; (3) at least 3 urinary urgency incontinence episodes on a 7-day bladder diary; and (4) serum 25(oh)d level (vitamin d) is \<30 ng/ml. women who currently take a bladder medications (anticholinergic) for ui symptom control may enroll into the study if they agree to (1) cease taking these medications at least two weeks before the pre-intervention assessment and (2) not take these medications during the study's treatment and assessment period. exclusion criteria: (1) neurologic diseases known to affect ui; (2) diseases known to affect vitamin d absorption and metabolism; (3) prior pelvic floor radiation; (4) obstructive causes of ui;(6)current use of medications known to affect vitamin d levels; (7) uncontrolled diabetes (hemoglobin a1c\>9%); (8) albumin corrected serum calcium \> 11.0 mg/dl; (9)history of hyperparathyroidism; (10) currently untreated kidney stones; (11) post void residual urine volume \>200 ml; and, (12) current treatment with vitamin d \>=1000iu/day (if not willing to stop taking).

Keywords: urinary incontinence bowel incontinence vitamin d overactive bladder lower urinary tract symptoms quality of life
oxytocin in mri-hifu

Conditions: Fibroid; Adenomyosis

Summary: capability of oxytocin in improving the efficacy of mri-hifu is studied. patients undergoing mri-hifu treatment are given oxytocin during treatment and the efficacy of the treatment will be analysed by patient reported symptom questionnaires and imaging data.


Eligibility criteria:
inclusion criteria: * patients undergoing mri-hifu -treatment * patients assessed for suitability to mri-hifu treatment * willingness to participate in trial exclusion criteria: * known allergy to syntocinon/oxytocin * elevated blood pressure * ischemic heart disease * long qt- interval

Keywords: oxytocin mri-hifu fibroid adenomyosis
sildenafil for treatment of priapism in men with sickle cell anemia

Conditions: Sickle Cell Disease; Priapism

Summary: this research is being done to evaluate if the phosphodiesterase type 5 (pde5) inhibitor sildenafil has an effect on the frequency of recurrent priapism and the quality of life of males with sickle cell disease (scd).

the proposed research is designed to investigate the utility of continuous, long-term pde 5 inhibitor therapy as an intervention for recurrent ischemic priapism, a disorder of non-willful, excessive penile erection, in patients with scd. although precise prevalence figures are not available, priapism in scd is highly prevalent and thought to afflict approximately 40% of males, based on available literature. additionally, the disorder exacts devastating consequences, including erectile tissue necrosis, erectile dysfunction, and psychological distress. management of this disorder remains challenging because the mechanisms underlying priapism are incompletely understood.

Eligibility criteria:
inclusion criteria: * ages 14 to 45, inclusive * episodes of prolonged penile erection in the absence of sexual interest or desire, with an average frequency of at least twice weekly, when averaged over the previous four weeks * able to provide informed consent or assent exclusion criteria: * use of chronic nitrates or recreational use of nitrate containing products * use of a pde5 (phosphodiesterase type 5)inhibitor within the previous two weeks * alcohol use exceeding two standard drinks daily * hypersensitivity to sildenafil * estimated glomerular filtration rate \<50ml/min * known cirrhosis * retinitis pigmentosa * necessary use of a p450 3a4 inhibitor (a drug which can increase plasma levels of sildenafil when taken together)

Keywords: priapism sickle cell disease sildenafil phosphodiesterase type 5 inhibitor